GSE239844 crizotinib 1 v 2 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE239844_crizotinib_1_v_2_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE239844_crizotinib_1_v_2_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE239844_crizotinib_1_v_2_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE239844_crizotinib_1_v_2_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

H19 imprinted maternally expressed transcript

Gene

THAP9 antisense RNA 1

Gene

non-coding RNA activated by DNA damage

Gene

long intergenic non-protein coding RNA 665

Gene

RNA polymerase II subunit J3

Gene

FGD5 antisense RNA 1

Gene

small nucleolar RNA host gene 7

Gene

long intergenic non-protein coding RNA 667

Gene

PAXX non-homologous end joining factor

Gene

zinc finger protein 883

  • Gene

    H19 imprinted maternally expressed transcript


  • Gene

    THAP9 antisense RNA 1


  • Gene

    non-coding RNA activated by DNA damage


  • Gene

    long intergenic non-protein coding RNA 665


  • Gene

    RNA polymerase II subunit J3


  • Gene

    FGD5 antisense RNA 1


  • Gene

    small nucleolar RNA host gene 7


  • Gene

    long intergenic non-protein coding RNA 667


  • Gene

    PAXX non-homologous end joining factor


  • Gene

    zinc finger protein 883

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.